ArticleCancers2022

Additive Intralesional Interleukin-2 Improves Progression-Free Survival in a Distinct Subgroup of Melanoma Patients with Prior Progression under Immunotherapy.

David Rafei-Shamsabadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.